Double-stranded sirna inhibiting HSD17b13 expression and conjugate thereof
WO2026233265A1PCT designated stage Publication Date: 2026-11-12ZHEJIANG YANGLI PHARMACEUTICAL TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- PCT/CN2026/094572
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-06
- Filing Date
- 2026-04-30
- Publication Date
- 2026-11-12
Smart Images

Figure CN2026094572_12112026_PF_FP_ABST
Abstract
A double-stranded siRNA inhibiting HSD17B13 expression and a conjugate thereof. The double-stranded siRNA inhibiting HSD17B13 expression comprises a sense strand and an antisense strand. The antisense strand comprises at least 15, 16, 17, 18, 19, 20, 21, 22, or 23 contiguous nucleotides in the sequence shown in SEQ ID NO: 1; or the antisense strand comprises at least 15, 16, 17, 18, 19, 20, 21, 22, or 23 contiguous nucleotides in the sequence shown in SEQ ID NO: 3. One or more nucleotide residues in the nucleotide sequence of the sense strand and / or the antisense strand are replaced with r, which is represented by formula I. The siRNA has good inhibitory activity against HSD17B13 mRNA in vitro or in vivo.
Need to check novelty before this filing date? Find Prior Art
